Astımlı hastalarda rosuvastatin tedavisinin havayolu inflamatuvar belirteçleri ve yaşam kalitesi göstergeleri üzerine etkisi
Amaç: Statinler kan lipid düzeylerinde azalma sağlamakla beraberaynı zamanda pleiotropik ve anti-inflamatuvar etkileri olan ilaçlardır.Statinlerin bir çok inflamatuvar hastalıkta yararlı etkileri gösterilmişolmasına karşın sonuçlar halen tartışmalıdır. Bu çalışmanın amacıastım hastalarında rosuvastatin tedavisinin klinik ve anti-inflamatuvaretkilerini incelemektir.Hastalar ve Yöntem: Astım hastalarında vaka-control çalışmasıplanlanmıştır. Toplam 136 astım hastası incelenmiş ve 74 hastaçalışmaya uygun bulunarak dahil edilmiştir. Elli bir hasta çalışmayıtamamlayabilmiştir. Hastalar başlangıçta yapılan kan tahlilinde serumdüşük dansiteli lipoprotein (LDL) seviyesine göre iki gruba ayrılmıştır,LDL düzeyi 130mg/dL üzerinde olan 25 hasta mevcut tedavilerine ekolarak 8 hafta boyunca 40mg rosuvastatin tedavisi alırken, 26 hastakontrol grubu olarak almakta oldukları tedaviye devam etmişlerdir.Her iki gruptaki hastalar, başlangıçta ve 8. haftanın sonunda solunumfonksiyon testi (SFT), bronş provokasyon testi (PD20), indüktebalgamda serum inflamatuvar belirteçleri, astım kontrol testi (AKT) veyaşam kalitesi skorları (QoL) ile değerlendirilmişlerdir.Bulgular: Statin kullanan grupta 8. hafta sonunda SFT’de FEV1/FVC (pp) (%85,8±11,1 vs .%90,2±8,8 P<0,043), FEF % 25-75 (%63,6±7,8 vs %74,6±8,4, P<0.0001) ve FEF25-75(L/sc) (3,51±0,4 vs4,1±0,4 P<0,05) düzelme saptanırken statin kullanmayan grupta anlamlıfark saptanmamıştır (P>0,05). Rosuvastatin tedavisi ile indükte balgameosinofilisinde (P<0,05); IL-6 ve TNF-alfa seviyelerinde azalma(P<0,05) saptanırken, AKT ve QoL skorları ve bronş provakasyontestinde anlamlı değişiklik saptanmamıştır.Sonuç: Bu çalışmada, astım hastalarında rosuvastatin 40mg ile8 haftalık tedavi sonrasında periferik eosinofili, total IgE seviyesi,indükte balgamda inflamatuvar belirteçlerde anlamlı düzeyde azalmasaptanmıştır. Yine SFT parametrelerinde düzelme izlenmiştir ancakbuna karşın AKT ve QoL skorlarında değişim saptanmamıştır.Busonuçlara göre rosuvastatin tedavisinin astım hastaları üzerinde birtakım potensiyel anti-inflamatuar etkileri bulunmaktadır. Rosuvastatininklinik etkilerinin saptanması için daha fazla sayıda randomize çalışmayaihtiyaç vardır.
Influence of rosuvastatin treatment on airway inflammatory markers and health related quality of life domains in asthmatic patients
Objectives: Statins are lipid lowering agents which have pleiotropic andanti-inflammatory effects. Beneficial effects of statins have been shownin many inflammatory and asthmatic diseases. However, the results arestill not consistent. The aim of this study is to determine the clinical andanti-inflammatory effects of rosuvastatin in asthmatic patients.Patients and Metods: A case control study among asthmaticpatients was conducted. One hundred and thirty-six participants werescreened. Seventy-four patients were eligible. Fifty-one patientshave completed the trial. Twenty-five patients with blood levels oflow-density-lipoprotein (LDL) above 130mg/dL, were treated withrosuvastatin 40mg for 8 weeks in addition to their standard treatmentfor asthma; 26 asthmatic patients were followed as control group. Inboth groups baseline and 8th week evaluation were recorded includingpulmonary function test (PFT), bronchial provocation test (PD20),induced sputum and serum inflammatory markers, asthma control test(ACT) and quality of life scores (QoL).Results: Statin group showed improvement in FEV1/FVC (pp)(85.8±11.1% vs 90.2±8.8% P<0.043), FEF 25-75 % (63.6±7.8 %vs 74.6±8.4 %, P<0.0001) and FEF25-75(L/sc) (3.51±0.4 vs 4.1±0.4P<0.05) and no change was seen in non-statin group (P>0.05) at theend of the 8-week treatment. Treatment with rosuvastatin resulted indecreased sputum eosinophilia percentage (P<0.05); IL-6 and TNFalphalevels (P<0.05) however, bronchial challenge test, ACT and QoLdomains did not change in both groups (P>0.05).Conclusion: An 8-week treatment with 40mg rosuvastatin in asthmadecreased the peripheral eosinophilia, total IgE levels and inflammatorymarkers in the induced sputum samples. Beneficial effects in PFT havealso been observed. However, ACT and QoL domains were not affected.The implication of this study is that rosuvastatin could potentially haveanti-inflammatory effects on asthmatic airways. Prospective randomisedtrials to evalute the clinical effects of rosuvastatin are warranted.
___
- Corsini A, Maggi FM, Catapano AL. Pharmacology of
competitive inhibitors of HMG-CoA reductase. Pharmacol
Res 1995;31:9-27. doi: 1043-6618(95)80042-5
- Hothersall EJ, Chaudhuri R, McSharry C, et al. Effects
of atorvastatin added to inhaled corticosteroids on lung
function and sputum cell counts in atopic asthma. Thorax
2008;63:1070-5. doi: 10.1136/thx.2008.100198
- Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly
recognized type of immunomodulator. Nature Medicine
2000;6:1399-402. doi: 10.1038/82219
- Zeki AA, Oldham J, Wilson M, et al. Statin use and
asthma control in patients with severe asthma. BMJ Open
2013;3:e003314. doi: 10.1136/bmjopen-2013-003314
- Braganza G, Chaudhuri R, McSharry C, et al. Effects of shortterm
treatment with atorvastatin in smokers with asthma. A
randomized controlled trial. BMC Pulm Med 2011;11:16.
doi: 10.1186/1471-2466-11-6.
- Christiansen SC, Eddleston J, Wagelie-Steffen A, Yang
AJ, Chen W, Zuraw BL. Influence of HMC-CoA reductase
inhibitors on asthma severity. J Allergy Clin Immunol
2009;123:No 2 S84 Abst 313
- Ostroukhova M, Kouides RW, Friedman E. The effect of
statin therapy on allergic patients with asthma. Ann Allergy
Asthma Immunol 2009;103:463-8. doi: 10.1016/S1081-
1206(10)60261-X
- Report G. Global Initiative for Asthma:GINA Report, Global
Strategy for Asthma Management and Prevention- updated
2012. 2012. Available at : (http://www.ginasthma.org). 2012
(Accessed:
- Standardization of Spirometry, 1994 Update. American
Thoracic Society. American Journal of Respiratory and
Critical Care Medicine 1995;152:1107-36. doi: 10.1164/
ajrccm.152.3.7663792
1
Chai H, Farr RS, Froehlich LA, et al. Standardization of
bronchial inhalation challenge procedures. J Allergy Clin
Immunol 1975;56:323-7.
- Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test:
reliability, validity, and responsiveness in patients notpreviously followed by asthma specialists. J Allergy Clinical
Immunol 2006;117:549-56. doi: 10.1016/j.jaci.2006.01.011
- Pinnock H, Sheikh A, Juniper EF. Evaluation of an
intervention to improve successful completion of the Mini-
AQLQ: comparison of postal and supervised completion.
Primary Care Respiratory Journal : Journal of the General
Practice Airways Group 2004;13:36-41. doi: 10.1016/j.
pcrj.2003.11.004
- Efthimiadis A, Jayaram L, Weston S, Carruthers S, Hargreave
FE. Induced sputum: time from expectoration to processing.
Europ Respir J 2002;19:706-8.
- Foumani S, Nejatifar F, Forghan Parast K, Heidarinejad S,
Mortazhejri G. Effects of atorvastatin in asthmatic patients
under treatment with high dose oral or inhaled steroid.
(Abstract) European Respirotary Society Annual Congress,
Barcelona, Spain, September 18-22, 2010. (372).
- Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M,
Lipworth BJ. Simvastatin does not exhibit therapeutic antiinflammatory
effects in asthma. J Allergy Clinic Immunol
2007;119:328-35 doi: 10.1016/j.jaci.2006.10.014
- Fahimi F, Jamaati H, Taheri ZM, Fakharian A, Salamzadeh J.
Does atorvastatin have effect on lung function and morbiditiy
as add on therapy in asthmatic patients? Europ Respir J
2007:490s:2960.
- Moini A, Azimi G, Farivar A. Evaluation of atorvastatin
for the treatment of patients with asthma: a double-blind
randomized clinical trial. Allergy, Asthma Immunol Res
2012;4:290-4. doi: 10.4168/aair.2012.4.5.290
- Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR.
Simvastatin in the treatment of asthma: lack of steroid-sparing
effect. Thorax 2010;65:891-6. doi: 10.1136/thx.2010.138990
- Feschenko Y, Lashyna L, Kramarskaya N, Polianska M,
Matvienko J. Clinical and functional effectiveness of
atorvastatin in complex therapy of severe bronchial asthma.
(Abstract) European Respiratory Society Annual Congress,
Berlin, Germany, October 4-8 2009. [E4554].
- Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence
for statin pleiotropy in humans: differential effects of
statins and ezetimibe on rho-associated coiled-coil
containing protein kinase activity, endothelial function, and
inflammation. Circulation 2009;119:131-8. doi: 10.1161/
CIRCULATIONAHA.108.813311
- Malek Mohammad M, Fahimi F, Fakharian A, et al.
Methacoline Challenge test as an evaluator of response
to statins in bronchial hyperresponsiveness. Iranian J
Pharmaceutical Res 2012;11:969-77.
- Deanin GG, Cutts JL, Pfeiffer JR, Oliver JM. Role of
isoprenoid metabolism in IgE receptor-mediated signal
transduction. J Immunol 1991;146:3528-35.
- Roche CM, Trimble ER, Ennis M. Effect of in vivo and invitro lovastatin treatment on mast cell activation. Int Arch
Allergy Immunol 1995;108:240-6.
- Krauth MT, Majlesi Y, Sonneck K, et al. Effects of
various statins on cytokine-dependent growth and IgEdependent
release of histamine in human mast cells. Allergy
2006;61:281-8. doi: 10.1111/j.1398-9995.2006.00997.x
- Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY. Anti-inflammatory
mechanism of simvastatin in mouse allergic asthma
model. Eur J Pharmacol 2007;557:76-86. doi: 10.1016/j.
ejphar.2006.11.027
- Yilmaz F, Gunduz H, Arinc H, et al. Does the prevalence
of nasal polyps increase in patients using statins? Adv Ther
2007;24:1330-9.
- Kim YM, Kim YS, Jeon SG, Kim YK. Immunopathogenesis
of allergic asthma: more than the th2 hypothesis. Allergy
Asthma Immunol Res 2013;5:189-96. doi: 10.4168/
aair.2013.5.4.189
- Kips JC. Cytokines in asthma. Eur Respir J Suppl
2001;34:24s-33s
- Pennings HJ, Kramer K, Bast A, Buurman WA, Wouters
EF. Tumour necrosis factor-alpha induces hyperreactivity in
tracheal smooth muscle of the guinea-pig in vitro. Eur Respir
J 1998;12:45-9.
- Howarth PH, Babu KS, Arshad HS, et al. Tumour
necrosis factor (TNFalpha) as a novel therapeutic target
in symptomatic corticosteroid dependent asthma. Thorax
2005;60:1012-8. doi: 10.1136/thx.2005.045260
- Berry MA, Hargadon B, Shelley M, et al. Evidence of a role
of tumor necrosis factor alpha in refractory asthma. N Engl J
Med 2006;354:697-708. doi:10.1056/NEJMoa050580
- Camara J, Jarai G. Epithelial-mesenchymal transition in
primary human bronchial epithelial cells is Smad-dependent
and enhanced by fibronectin and TNF-alpha. Fibrogen Tiss
Rep 2010;3:2. doi: 10.1186/1755-1536-3-2
- Shyu KG, Chua SK, Wang BW, Kuan P. Mechanism of
inhibitory effect of atorvastatin on resistin expression induced
by tumor necrosis factor-alpha in macrophages. J Biomed Sci
2009;16:50. doi: 10.1186/1423-0127-16-50
- Awad AS, El Sharif A. Immunomodulatory effects of
rosuvastatin on hepatic ischemia/reperfusion induced injury.
Immunopharmacol Immunotoxicol 2010;32:555-61. doi:
10.3109/08923970903575716
- Rubin BK. Statins for the treatment of asthma: a discovery
well, dry hole or just snake oil. Thorax 2009;64:4-5. doi:
10.1136/thx.2008.106757
- Fessler MB, Jaramillo R, Crockett PW, Zeldin DC.
Relationship of serum cholesterol levels to atopy in the US
population. Allergy 2010;